



## Alissa Dei Cas

Medizinische Onkologie und Hämatologie · Dept. I

### Contact

Alissa Dei Cas  
St. Gallen

T +41 71 494 6103  
Alissa.DeiCas@kssg.ch

### Units

Medizinische Onkologie und Hämatologie

## Publications (0)

No results found.

## Projects (5)

**Addition of Darolutamide to first line treatment of mCRPC: a randomized open label phase II trial.**

*Clinical Studies - Oct 31, 2024 - Dec 31, 2028*

*Ongoing*

**SAKK 66/22 - Invincible 4 SAKK**

*Clinical Studies - Oct 17, 2024 - Dec 31, 2029*

*Ongoing*

**A multicenter, open-label, randomized, phase 2 study of venetoclax and azacitidine plus cusatuzumab versus venetoclax and azacitidine alone in newly diagnosed AML patients who are not candidates for intensive therapy**

*Clinical Studies - Oct 7, 2024 - Oct 9, 2028*

*Ongoing*

**MS201924\_0002**

*Clinical Studies - Sep 30, 2024 - Sep 30, 2028*

*Ongoing*

**A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING IBERDOMIDE, DARATUMUMAB AND DEXAMETHASONE (IberDd)VERSUS DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (Dvd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) (EXCALIBER-RRMM)**

*Clinical Studies - Aug 2, 2022 - Nov 14, 2024*

*Completed*